Physician profile
Anitha Menon
NPI 1720030497
$4,814.92
in general payments reported to CMS, 2019-2025
37 companies · $454 in 2025
The $454 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,329 · 2020: $530 · 2021: $875 · 2022: $342 · 2023: $776 · 2024: $509 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,739.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,046.61 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $542.24 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Amgen INC. | $313.58 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $300.00 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $284.71 | 2019-2023 | Jardiance, Emgality |
| Glaxosmithkline, LLC. | $242.12 | 2020-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Pfizer INC. | $235.18 | 2019-2023 | |
| Amarin Pharma, INC. | $212.12 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $208.29 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $177.15 | 2019-2021 | |
| Abbvie INC. | $130.78 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $102.78 | 2019-2021 | |
| Corcept Therapeutics | $102.02 | 2023-2024 | Korlym |
| Kowa Pharmaceuticals America, INC. | $94.24 | 2019-2023 | Seglentis |
| Depuy Synthes Sales INC. | $79.22 | 2019-2024 | Orthovisc |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $74.71 | 2024-2025 | Skyclarys |
| Phadia US INC. | $73.21 | 2021-2025 | Immunocap |
| Bayer Healthcare Pharmaceuticals INC. | $63.93 | 2022-2023 | |
| Exact Sciences Corporation | $61.03 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $55.81 | 2024-2025 | Voquezna |
| Seqirus USA INC | $52.82 | 2021-2025 | Flucelvax, Fluad |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.27 | 2019 | |
| Allergan, INC. | $43.10 | 2020-2021 | |
| Scpharmaceuticals INC. | $28.50 | 2025 | |
| Shield Therapeutics INC | $25.73 | 2023 | Accrufer |
| Almatica Pharma LLC | $23.83 | 2023 | Gralise, Loreev Xr |
| Eisai INC. | $23.21 | 2021 | |
| Scilex Pharmaceuticals INC. | $21.42 | 2022 | |
| Astellas Pharma US INC | $20.33 | 2021 | |
| Shire North American Group INC | $19.20 | 2019 | |
| Ironwood Pharmaceuticals, INC | $19.14 | 2020 | |
| Abbott Laboratories | $18.35 | 2022 | |
| Hikma Pharmaceuticals USA | $16.17 | 2020 | |
| Sanofi Pasteur INC. | $15.47 | 2020 | |
| Aytu Biopharma, INC. | $14.89 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.06 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $11.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anitha Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.